Palabras clave
Hipertensión Arterial Sistémica
Mortalidad
Unidad de Terapia Intensiva
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Correlacionar la presencia de Hipertensión Arterial Sistémica en pacientes con COVID-19 ingresados en la Unidad de Terapia Intensiva de un hospital de Juiz de Fora – MG con el desenlace clínico presentado. Métodos: Se trata de un estudio observacional y transversal, en el que se analizaron 179 historias clínicas de pacientes ingresados con COVID-19 en la Unidad de Cuidados Intensivos de un hospital de Juiz de Fora – MG, de junio de 2020 a enero de 2021. Resultados: Se observaron tasas de mortalidad más altas en personas de mayor edad. La presencia de Hipertensión Arterial Sistémica y el sexo del paciente no resultaron ser factores predictivos de gravedad, ya que las pruebas ANOVA no indicaron diferencia estadística significativa. Conclusión: El mayor riesgo de casos graves y muertes por COVID-19 se observó en personas mayores, lo que permite desarrollar una conducta profesional adecuada a este colectivo específico, evitando resultados desfavorables.
Referencias
CHAN JFW, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient after visiting Wuhan. Emerging Microbes & Infections, 2020; 9(1): 221-236.
CHEN N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020; 395(10223): 507-513.
CHENCHULA S, et al. Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression. Scientific Reports, 2023; 13(1):6415.
CUNHA DE OLIVEIRA ML e FERNANDES SILVA D. Epidemiologia da COVID-19: comparação entre boletins epidemiológicos. Com. Ciências Saúde [Internet]. 8º de maio de 2020 [citado 16º de fevereiro de 2024];31(Suppl1):61-74. Disponível em: https://revistaccs.escs.edu.br/index.php/comunicacaoemcienciasdasaude/article/view/661
DESSIE ZG e ZEWOTIR T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infectious Diseases, 2021; 21(1):855.
DU L, et al. The spike protein of SARS-CoV – a target for vaccine and therapeutic development. Natural Reviews Microbiology, 2009; 7(3): 226-236.
DU Y, et al. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2021; 31(3): 745-755.
GALBAGE T, et al. Systematic Review and Meta-Analysis of Sex-Specific COVID-19 Clinical Outcomes. Frontier Medicine (Lausanne), 2020; 7:348.
GENG J, et al. Chronic Diseases as a Predictor for Severity and Mortality of COVID-19: A Systematic Review With Cumulative Meta-Analysis. Frontier Medicine (Lausanne), 2021; 8: 588013.
GUIMARÃES-TEIXEIRA E, et al. Comorbidades e saúde mental dos trabalhadores da saúde no Brasil. O impacto da pandemia da COVID-19. Ciência & Saúde Coletiva, 2023; 28(10):2823-2832.
HOFFMANN M, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020; 181(2): 271-280.
HUANG C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 2020; 395(10223): 497-506.
MAHAMAT- SALEH Y, et al. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. BMJ Open, 2021; 25;11(10):e052777.
NOOR FM e ISLAM MM. Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis. Journal of Community Health, 2020; 45(6):1270-1282.
RAVICHANDRAN B, et al. SARS-CoV-2 and hypertension. Physiological Reports, 2021; 9(11): 1-14.
SILVA, et al. FATORES INTERVENIENTES NO TEMPO DE INTERNAÇÃO HOSPITALAR DE PACIENTES COM COVID-19. Revista Enfermagem Atual In Derme, 2023; 97(2): e023084-e023084.
The jamovi project (2021). JAMOVI. (Version 2.2) [Computer Software]. Retrieved from https://www.jamovi.org.
World Health Organization. Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV). Disponível em: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov). Acessado em: 15 de Fevereiro de 2024.
WU F, et al. A new coronavirus associated with human respiratory disease in China. Nature, 2020; 579 (7798): 265-269.
ZHANG JJY, et al. Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19. A systematic review, meta-analysis, and meta-regression analysis. Clinical Infectious Diseases, 2020; 71(16): 2199-2206.